A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. - Wikidata - wikimedia - TriplyDB

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

http://www.wikidata.org/entity/Q33897645

about

Optimized expression of Plasmodium falciparum erythrocyte membrane protein 1 domains in Escherichia coli Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system The globalization of traditional medicine in northern peru: from shamanism to molecules.Plasmodium falciparum merozoite surface protein 1 blocks the proinflammatory protein S100P Malaria modeling: In vitro stem cells vs in vivo models Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1 Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children.Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1 Changes in antigen-specific cytokine and chemokine responses to Plasmodium falciparum antigens in a highland area of Kenya after a prolonged absence of malaria exposure.Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.IFNγ Responses to Pre-erythrocytic and Blood-stage Malaria Antigens Exhibit Differential Associations With Past Exposure and Subsequent Protection.Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142).Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia.A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila.Erythropoiesis stimulating agents: approaches to modulate activity.Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.[Humoral immune anti-Plasmodium falciparum AMA1 and MSP1 response in two ethnic groups living in sympatry in Mali].

P2860

Q24802878-C3D5BB4D-8A84-4AF8-9B3B-0B1F98223D41 Q26700012-2100D0D7-BBD7-4337-B640-5DDF741E8467 Q26830049-50148297-908C-44EC-BE06-021552475962 Q27972785-30921F48-BD12-44FF-A898-FCC326E6DCF2 Q28071293-BEFB4470-9B8F-47EB-8779-21E0928CAAE2 Q28484081-045F3A90-79E8-4A30-BC54-70765F922C9D Q33264521-F141E5B6-3F1B-4824-8B6C-51028DABFD37 Q33303670-9FDE8B95-077A-48E0-9C64-9DB61697CDE4 Q33350210-A9ECD356-AB8D-40CF-B2E0-8AB9F2AA2201 Q33415066-11C15D3C-2AE4-454F-B2EA-124DFC6D0ADC Q33558061-BE7C1674-1FF6-4A38-8BE5-1528FEE64A0C Q33883252-C24B4F4D-9137-4901-B56A-C91685E66E7B Q34260615-587FB710-7F1B-4B5C-BF38-5D053E61D268 Q34260722-A1A70549-4570-488F-B3D6-198FAB8D8EEB Q34290768-7585FD0F-F259-4837-B7BD-E190DFA9CE73 Q34298486-4BD48200-7467-48C4-8B87-1717BDCBFA55 Q34940333-9C416198-BE23-4C63-BF4B-BC081FBA4759 Q34975629-A0572BDC-B3F6-43ED-8FAC-A9E76F6C24E9 Q35550770-5AA995E7-CC80-4D39-B64D-37770FC49008 Q35762375-122D6003-BE17-4AD3-A0C8-BC294C27291F Q35998776-F465A4FD-A99E-4862-97DB-CE3458E41FEA Q36639261-FBEA0FBF-95FB-4F75-9AE5-A872647EEDDF Q36812832-E9856465-6ADE-4EBB-9D9A-79789686EDD7 Q37425845-CD7B6CCB-E162-4A4B-99D4-5885FE59FF9A Q37448753-A791B83E-5169-48FF-B19A-5E47DEA82439 Q37452080-82E85BDD-0216-4752-A749-1E58C1B108A2 Q37523653-A0DA68DF-6521-4EA0-BF94-5F2F2A80BB28 Q37529646-E599204D-5030-4231-AA63-55986E2A3A34 Q38121067-3E118CBB-741C-4AB6-B4EF-E22E0B9B8337 Q38942086-9686834A-5F60-4C29-AEE3-8E60078A8B51 Q38962773-AFBD211E-024D-4495-BCB9-2C44490FACE3 Q46694488-9762F5FC-5743-48B7-A4AD-421374E0126D

P2860

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

http://www.wikidata.org/entity/Q33897645

description

2001 nî lūn-bûn

@nan

2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

A recombinant vaccine expresse ...... ge with Plasmodium falciparum.

@ast

A recombinant vaccine expresse ...... ge with Plasmodium falciparum.

@en

type

label

A recombinant vaccine expresse ...... ge with Plasmodium falciparum.

@ast

A recombinant vaccine expresse ...... ge with Plasmodium falciparum.

@en

prefLabel

A recombinant vaccine expresse ...... ge with Plasmodium falciparum.

@ast

A recombinant vaccine expresse ...... ge with Plasmodium falciparum.

@en

P1433

Q33897645-2EDE873D-A7CE-47BA-BC74-4BE0109B3E52

P1476

Q33897645-7151903E-F95B-4459-AEBE-3085CA5628FD

P2093

Q33897645-11E875B7-8703-4795-A9D2-F19D587ED3B4

Q33897645-17482007-2E51-4BC2-A8E1-4BB952BB1D57

Q33897645-2D3C6317-75D6-4003-AD69-2E57BACB7090

Q33897645-36CF2212-70F9-41DA-B0C1-9C27DDB08864

Q33897645-47FDE689-42E4-4D94-B3BC-75713C156511

Q33897645-534DFA1E-4059-4E57-850A-C76DBA479175

Q33897645-83221036-C1B0-44DD-AD46-151FD3C1EC01

Q33897645-9596FAE4-C5A2-45C3-8922-BD2640CFF0BC

Q33897645-9DDC3788-44E6-4A9A-B930-9553A9D97141

Q33897645-A7715193-EE37-444E-932F-DCE84C91FD4E

P2860

Q33897645-0BED606B-C302-4570-BE86-FD775703A07C

Q33897645-1793F32F-2BDB-4087-9F81-3520833CCB87

Q33897645-1EC78F1E-2259-4EAC-8B88-A69A285F5875

Q33897645-3C03E085-6DD8-4A92-8E34-93C9949650A7

Q33897645-415CB3A0-DBB4-4EB2-BA80-B653315CA057

Q33897645-4460489C-B729-4C62-833F-A1B9943D7ACA

Q33897645-455DCADB-0D19-41D6-92EC-F3EF48EF1657

Q33897645-4BFC8305-5FB0-4D96-85AA-54D44D34AAA2

Q33897645-672025EB-8F09-41ED-8FE8-525D64F6A0AC

Q33897645-7596C402-1FFE-469F-9720-A54422816D36

P304

Q33897645-94DA110F-E346-4ABC-99D5-4537F5633396

P31

Q33897645-A5B5891E-0A2F-4E22-B5F4-B7FC66DBA2BB

P356

Q33897645-575EA8DC-8A38-4030-A89E-22FB96A1CB39

P407

Q33897645-BAC26199-66F9-4D27-8750-0E0D2D2766D0

P433

Q33897645-E204E57F-734A-4888-81EF-DBACE1152FC6

P478

Q33897645-CF4DD308-FDEC-4532-B66C-E456BA57C9BB

P50

Q33897645-06A76CE2-E2E1-428A-8B8A-62B910839184

Q33897645-A31EE46F-E51F-45BD-8FA1-C0E9C5F88F75

P577

Q33897645-83513F39-4D4D-40FA-97B6-9315664A477B

P5875

Q33897645-BC861C0A-CA55-450E-B685-C10A1FA9BCE9

P698

Q33897645-5CC9F667-B6A6-47AE-8F22-1E3A9FA7304B

P921

Q33897645-426F2473-A8AC-4F5F-A5D3-42CAFEC22B12

P932

Q33897645-4793301B-9BDB-4C19-A4F4-2F6DE5C28247

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A recombinant vaccine expresse ...... ge with Plasmodium falciparum.

@en

P2093

Allan Saul

http://www.w3.org/2001/XMLSchema#string

Anthony W Stowers

http://www.w3.org/2001/XMLSchema#string

David C Kaslow

http://www.w3.org/2001/XMLSchema#string

Harry Meade

http://www.w3.org/2001/XMLSchema#string

Lanling Zou

http://www.w3.org/2001/XMLSchema#string

Li-how Chen Lh

http://www.w3.org/2001/XMLSchema#string

Lynn Lambert

http://www.w3.org/2001/XMLSchema#string

Michael C Kennedy

http://www.w3.org/2001/XMLSchema#string

Timothy J Rice

http://www.w3.org/2001/XMLSchema#string

Yanling Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of Plasmodium falciparum

Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice.

Protein glycosylation in the malaria parasite.

Biopharmaceutical production in transgenic livestock.

Transgenic milk as a method for the production of recombinant antibodies.

Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys.

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.

A malaria merozoite surface protein (MSP1)-structure, processing and function.

Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites.

Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

P304

339-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.012590199

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Louis H. Miller

P577

2001-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11605729

http://www.w3.org/2001/XMLSchema#string

P698

11752405

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

P932

117562

http://www.w3.org/2001/XMLSchema#string